In this concise presentation, Dr. Daniel Kuritzkes discusses recent data on new long-acting injectable ART.
In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.
Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.
Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Learn why one patient feels that long-acting ART gave her a lot of her life back.